The estimated Net Worth of Douglas B Given is at least $8.38 Milione dollars as of 11 January 2024. Douglass Given owns over 2,911 units of Arrowhead Pharmaceuticals stock worth over $2,716,148 and over the last 12 years he sold ARWR stock worth over $5,135,500. In addition, he makes $525,558 as Chairman of the Board at Arrowhead Pharmaceuticals.
Douglass has made over 19 trades of the Arrowhead Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 2,911 units of ARWR stock worth $110,793 on 11 January 2024.
The largest trade he's ever made was selling 68,000 units of Arrowhead Pharmaceuticals stock on 22 February 2019 worth over $1,305,600. On average, Douglass trades about 5,115 units every 95 days since 2012. As of 11 January 2024 he still owns at least 129,711 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Douglass Given stock trades at the bottom of the page.
Dr. Douglass Bruce Given M.D., Ph.D. serves as Chairman of the Board of the Company. Doug is Managing Partner at Health2047 Capital Partners LLC. He served as Health2047 Inc.’s Chief Executive from its founding in August 2015 until January 2018. Previously, Dr. Given spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sector-specific funds. He was associated with the partnership from 1999 to 2015. A physician and medical scientist by background, Dr. Given has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt and a serial entrepreneur, as well as a venture capitalist. In addition to a number of private companies, he led three public biotechnology and biopharmaceutical companies as CEO. Dr. Given has served on more than 20 public and private boards. He is currently a director at Health2047 Inc., board chair at Akiri Inc., Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc. and Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Stanford Institute for Economic Policy Research (SIEPR), and The Houston Methodist Research Institute.
As the Chairman of the Board of Arrowhead Pharmaceuticals, the total compensation of Douglass Given at Arrowhead Pharmaceuticals is $525,558. There are 7 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.
Douglass Given is 67, he's been the Chairman of the Board of Arrowhead Pharmaceuticals since 2013. There are no older and 16 younger executives at Arrowhead Pharmaceuticals.
Douglas's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone e Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: